Abstract
Genetic profiling in the randomized controlled phase 3 COMPOSE trial of 177Lu-edotreotide for well-differentiated aggressive grade 2/3 gastroenteropancreatic neuroendocrine tumors
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have